DouglasVCJosephsonSA. A proposed roadmap for inpatient neurology quality indicators. Neurohospitalist. 2011;1(1):8–15.
2.
LikoskyDJJosephsonSAColemanMFreemanWDBillerJ. Survey of current neurohospitalist practice. Neurol Clin Pract. 2012;2:319–327.
3.
SutterRMarschSFuhrPRueggS. Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study. Epilepsia. 2013;54(3):502–511.
4.
GaspardNForemanBJuddLM. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–1503.
5.
RosatiAL'ErarioMIlventoL. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology. 2012;79(24):2355–2358.
6.
LancasterEMartinez-HernandezEDalmauJ. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–189.
7.
PanditAKIhtishamKGargAGulatiSPadmaMVTripathiM. Autoimmune encephalitis: a potentially reversible cause of status epilepticus, epilepsy, and cognitive decline. Ann Indian Acad Neurol. 2013;16(4):577–584.
8.
Gil-NagelAElgerCBen-MenachemE. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013;54(1):98–107.
9.
MorrellMJon behalf of the RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology. 2011;77(13):1295–1304.